Oncolytics Biotech (TSE:ONC) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.

Oncolytics Biotech Stock Performance

The company’s fifty day simple moving average is C$14.90 and its 200-day simple moving average is C$14.90. The company has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.